Summary by Futu AI
Eli Lilly and Co, a major pharmaceutical company, is facing a shareholder proposal for increased transparency in its lobbying activities. The SEIU Benefit Plans Master Trust, which is relying on an exemption, has submitted written materials to encourage shareholders to vote for greater disclosure of Eli Lilly's direct and indirect lobbying expenditures at the upcoming annual shareholder meeting on May 6, 2024. The proposal, identified as Item #6 on the proxy card, requests that the company publish an annual report detailing its lobbying policies, procedures, and expenditures, including payments to tax-exempt organizations that endorse model legislation. Despite Eli Lilly's claim of sufficient current disclosures, the SEIU Trust argues that the company's disclosures are inadequate, particularly regarding state, foreign, and...Show More